Corixa Corporation

Type: Company
Name: Corixa Corporation
Nationality: United States
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

07/12/2005 Corixa stockholders approve $300M purchase by Glaxo

: Corixa stockholders approve $300M purchase by Glaxo(BizJournals.com) Corixa Corp. said its shareholders have approved the proposed purchase by GlaxoSmithKline plc., and the deal is now expected to close later Tuesday.Holders of the Seattle-based biotech ... [Published KBL Healthcare Ventures - Aug 08 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

11/28/2006 Magellan Biosciences Closes $50 Million Financing

Magellan Biosciences Closes $50 Million FinancingMichael F. Bigham and Daniel R. Omstead, Eng.ScD, Join Board of DirectorsCHELMSFORD, Mass., Nov. 28 /PRNewswire/ -- Magellan Biosciences, an emerging leader in clinical-diagnostic markets worldwide, announced ... [Published KBL Healthcare Ventures - Aug 08 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Celgene Reports Second Quarter 2014 Operating and Financial Results

By a News Reporter-Staff News Editor at Clinical Trials Week -- Celgene Corporation (NASDAQ:CELG) reported net product sales of $1,845 million for the second quarter of 2014, an 18 percent increase from the same period in 2013. Second quarter total revenue ... [Published HispanicBusiness.com - Jul 30 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

VBI Vaccines: A Company Ready For Breakthrough

Summary The team behind this company. The science VBIV is studying. Risks investing in VBIV.VBI Vaccines: A Company Ready for Breakthrough A company that I have been accumulating shares in is VBI Vaccines (NASDAQ: VBIV ). It is the kind of company ... [Published Seeking Alpha - Jul 30 2014]
First reported Mar 06 2014 - Updated Mar 06 2014 - 1 reports

Pertussis antibodies and uses thereof

Bordetella pertussis, the etiologic agent of whooping cough, is a highly infectious human pathogen with a strong capacity to infect the human respiratory tract (Kerr and Matthews, 2000). It is presently one of the ten most common causes of death from ... [Published PharmCast - Mar 06 2014]
First reported Mar 05 2014 - Updated Mar 05 2014 - 1 reports

Refrigerator-temperature stable influenza vaccine compositions

Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions ... [Published PharmCast - Mar 05 2014]
Entities: Virus, Influenza, Vaccine
First reported Feb 26 2014 - Updated Feb 26 2014 - 1 reports

Catalent Announces Two Senior Appointments to Expand Biologics Business

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced two senior appointments to further strengthen its global biologics business. ... [Published PRWeb - Feb 26 2014]

Quotes

...point-of-care CLIA- waived LeadCare II blood-lead-testing system," said Magellan President and Chief Executive Officer, Robert J Rosenthal, PhD. "This new funding will allow us to expand our growth through further new productproduct development as well as strategic acquisitions. We plan to expand our presence in products for clinical- diagnostics, hospital-based labs, and near-patient testing that improve health outcomes."
...momentum of our portfolio and support raising our 2014 guidance," said Bob Hugin , Chairman and Chief Executive Officer of Celgene Corporation . "We look forward to multiple milestones in the second half of the year, including the expansion of OTEZLA® into psoriasis and the further advancement of our pipeline." Second Quarter 2014 Financial Highlights Unless otherwise stated, all comparisons are for the second quarter of 2014 compared to the second quarter of...

More Content

All (7) | News (7) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
11/28/2006 Magellan Biosciences Closes $50 Mill... [Published KBL Healthcare Ventures - Aug 08 2014]
07/12/2005 Corixa stockholders approve $300M pu... [Published KBL Healthcare Ventures - Aug 08 2014]
Celgene Reports Second Quarter 2014 Operating a... [Published HispanicBusiness.com - Jul 30 2014]
VBI Vaccines: A Company Ready For Breakthrough [Published Seeking Alpha - Jul 30 2014]
Pertussis antibodies and uses thereof [Published PharmCast - Mar 06 2014]
Refrigerator-temperature stable influenza vacci... [Published PharmCast - Mar 05 2014]
Catalent Announces Two Senior Appointments to E... [Published PRWeb - Feb 26 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.